Cu²⁺-Coordinated NLG919: A Drug Delivery Nanoplatform to Activate Antitumor Immunity via Inducing Immunogenic Cell Death and Inhibiting Indoleamine 2,3-Dioxygenase-1

Abstract

Chemotherapeutic drug combination to activate systemic antitumor immunity is appealing to fight metastatic tumors. In this study, copper ion (Cu²⁺) is able to coordinate with NLG919, serving as a nanoplatform (designated as CuN) for drug delivery. Meanwhile, such a metal-coordinated nanomedicine can also activate systemic antitumor immunity through immunogenic cell death (ICD) induction and indoleamine 2,3-dioxygenase-1 (IDO1) inhibition. Some representing antitumor agents, including cinnamic acid, mitoxantrone, docetaxel, β-lapachone, tazemetostat and mocetinostat, can be encapsulated into CuN regardless of their different physicochemical characteristics. Taking β-lapachone for example, the drug-carrying CuN (designated as Lap@CuN) can catalyze the production of excessive reactive oxygen species (ROS) to suppress tumor cell proliferation and trigger a robust ICD to release damage associated molecular patterns (DAMPs). Consequently, Lap@CuN not only inhibits primary tumor growth through chemotherapy but also reactivates the immune cells to exert an abscopal effect. Benefiting from the immune modulatory effect, Lap@CuN reduces the lung metastasis while not causing obvious side effects on mice. This study presents a universal metal-coordinated nanoplatform for the delivery of chemotherapeutic combinations, offering new insights into the design of combination therapies that can potentiate immunotherapeutic responses.

Keywords

drug delivery / immunogenic cell death / metal-drug coordination

References

[1] K. M. Heinhuis, W. Ros, M. Kok, N. Steeghs, J. H. Beijnen, and J. H. M. Schellens, “Enhancing Antitumor Response by Combining Immune Checkpoint Inhibitors With Chemotherapy in Solid Tumors,” Annals of Oncology 30 (2019): 219–235.

[2] J. Li, Y. Wang, Y. Zhu, and D. Oupický, “Recent Advances in Delivery of Drug-Nucleic Acid Combinations for Cancer Treatment,” Journal of Controlled Release 172 (2013): 589–600.

[3] L. Kraehenbuehl, C. H. Weng, S. Eghbali, J. D. Wolchok, and T. Merghoub, “Enhancing Immunotherapy in Cancer by Targeting Emerging Immunomodulatory Pathways,” Nature Reviews Clinical Oncology 19 (2022): 37–50.

[4] L. Galluzzi, J. Humeau, A. Buqué, L. Zitvogel, and G. Kroemer, “Immunostimulation With Chemotherapy in the Era of Immune Checkpoint Inhibitors,” Nature Reviews Clinical Oncology 17 (2020): 725–741.

[5] J. Hou, R. Zhao, W. Xia, et al., “Pd-L1-mediated Gasdermin C Expression Switches Apoptosis to Pyroptosis in Cancer Cells and Facilitates Tumour Necrosis,” Nature Cell Biology 22 (2020): 1264–1275.

[6] X. Song, Z. Zhou, H. Li, et al., “Pharmacologic Suppression of B7-H4 Glycosylation Restores Antitumor Immunity in Immune-Cold Breast Cancers,” Cancer Discovery 10 (2020): 1872–1893.

[7] S. R. Woo, M. B. Fuertes, L. Corrales, et al., “Sting-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors,” Immunity 41 (2014): 830–842.

[8] J. Chen, Z. Lin, L. Liu, et al., “GOLM1 Exacerbates CD8⁺ T Cell Suppression in Hepatocellular Carcinoma by Promoting Exosomal PD-L1 Transport Into Tumor-Associated Macrophages,” Signal Transduction and Targeted Therapy 6 (2021): 397.

[9] W. Kim, T. H. Chu, H. Nienhüser, et al., “PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice,” Gastroenterology 160 (2021): 781–796.

[10] Y. Ding, Y. Wang, and Q. Hu, “Recent Advances in Overcoming Barriers to Cell-Based Delivery Systems for Cancer Immunotherapy,” Exploration 2 (2022): 20210106.

[11] L. Zhao, R. Zheng, L. Liu, et al., “Self-Delivery Oxidative Stress Amplifier for Chemotherapy Sensitized Immunotherapy,” Biomaterials 275 (2021): 120970.

[12] F. Liang, G. Z. Wang, Y. Wang, et al., “Tobacco Carcinogen Induces Tryptophan Metabolism and Immune Suppression via Induction of Indoleamine 2,3-Dioxygenase 1,” Signal Transduction and Targeted Therapy 7 (2022): 311.

[13] F. Zhao, C. Xiao, K. S. Evans, et al., “Paracrine wnt5a-β-catenin Signaling Triggers a Metabolic Program That Drives Dendritic Cell Tolerization,” Immunity 48 (2018): 147–160.e7.

[14] B. Peltanova, M. Raudenska, and M. Masarik, “Effect of Tumor Microenvironment on Pathogenesis of the Head and Neck Squamous Cell Carcinoma: A Systematic Review,” Molecular cancer 18 (2019): 63.

[15] Y. Li, C. Yang, Z. Liu, et al., “Integrative Analysis of CRISPR Screening Data Uncovers New Opportunities for Optimizing Cancer Immunotherapy,” Molecular cancer 21 (2022): 2.

[16] V. Panitz, S. Končarević, A. Sadik, et al., “Tryptophan Metabolism Is Inversely Regulated in the Tumor and Blood of Patients With Glioblastoma,” Theranostics 11 (2021): 9217–9233.

[17] G. L. Beatty, P. J. O'Dwyer, J. Clark, et al., “First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients With Advanced Solid Malignancies,” Clinical Cancer Research 23 (2017): 3269–3276.

[18] L. Galluzzi, A. Buqué, O. Kepp, L. Zitvogel, and G. Kroemer, “Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents,” Cancer Cell 28 (2015): 690–714.

[19] T. Nakahara, H. Uchi, A. M. Lesokhin, et al., “Cyclophosphamide Enhances Immunity by Modulating the Balance of Dendritic Cell Subsets in Lymphoid Organs,” Blood 115 (2010): 4384–4392.

[20] L. Zitvogel, L. Galluzzi, M. J. Smyth, and G. Kroemer, “Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance,” Immunity 39 (2013): 74–88.

[21] X. Wang, Y. Liu, C. Xue, et al., “A Protein-Based cGAS-Sting Nanoagonist Enhances T Cell-Mediated Anti-Tumor Immune Responses,” Nature Communications 13 (2022): 5685.

[22] X. Li, Z. Liu, A. Zhang, et al., “NQO1 Targeting Prodrug Triggers Innate Sensing to Overcome Checkpoint Blockade Resistance,” Nature Communications 10 (2019): 3251.

[23] A. S. Jeevarathinam, J. E. Lemaster, F. Chen, E. Zhao, and J. V. Jokerst, “Photoacoustic Imaging Quantifies Drug Release From Nanocarriers Via Redox Chemistry of Dye-Labeled Cargo,” Angewandte Chemie International Edition 59 (2020): 4678–4683.

[24] B. Li, J. Wang, Q. Gui, and H. Yang, “Drug-Loaded Chitosan Film Prepared Via Facile Solution Casting and Air-Drying of Plain Water-Based Chitosan Solution for Ocular Drug Delivery,” Bioactive Materials 5 (2020): 577–583.

[25] X. Jin, L. Zhu, B. Xue, X. Zhu, and D. Yan, “Supramolecular Nanoscale Drug-Delivery System With Ordered Structure,” National Science Review 6 (2019): 1128–1137.

[26] J. Guo, Z. Yu, D. Sun, Y. Zou, Y. Liu, and L. Huang, “Two Nanoformulations Induce Reactive Oxygen Species and Immunogenetic Cell Death for Synergistic Chemo-Immunotherapy Eradicating Colorectal Cancer and Hepatocellular Carcinoma,” Molecular Cancer 20 (2021): 10.

[27] Y. Li, J. Lin, P. Wang, et al., “Tumor Microenvironment Cascade-Responsive Nanodrug With Self-Targeting Activation and ROS Regeneration for Synergistic Oxidation-Chemotherapy,” Nano-Micro Letters 12 (2020): 182.

[28] H. Dianat-Moghadam, S. Abbasspour-Ravasjani, H. Hamishehkar, R. Rahbarghazi, and M. Nouri, “LXR Inhibitor SR9243-loaded Immunoliposomes Modulate Lipid Metabolism and Stemness in Colorectal Cancer Cells,” Medical Oncology 40 (2023): 156.

[29] H. Cheng, X. Y. Jiang, R. R. Zheng, et al., “A Biomimetic Cascade Nanoreactor for Tumor Targeted Starvation Therapy-Amplified Chemotherapy,” Biomaterials 195 (2019): 75–85.

[30] B. Zhang, J. Jiang, P. Wu, et al., “A Smart Dual-Drug Nanosystem Based on Co-Assembly of Plant and Food-Derived Natural Products for Synergistic HCC Immunotherapy,” Acta Pharmaceutica Sinica B 11 (2021): 246–257.

[31] W. Li, J. Chen, S. Zhao, et al., “High Drug-Loaded Microspheres Enabled by Controlled in-Droplet Precipitation Promote Functional Recovery After Spinal Cord Injury,” Nature Communications 13 (2022): 1262.

[32] D. Landesman-Milo and D. Peer, “Altering the Immune Response With Lipid-Based Nanoparticles,” Journal of Controlled Release 161 (2012): 600–608.

[33] B. Wang, X. He, Z. Zhang, Y. Zhao, and W. Feng, “Metabolism of Nanomaterials In Vivo: Blood Circulation and Organ Clearance,” Accounts of Chemical Research 46 (2013): 761–769.

[34] G. Yang, S. Z. F. Phua, A. K. Bindra, and Y. Zhao, “Degradability and Clearance of Inorganic Nanoparticles for Biomedical Applications,” Advanced Materials 31 (2019): 1805730.

[35] R. Zheng, L. Zhao, X. Chen, et al., “Metal-Coordinated Nanomedicine for Combined Tumor Therapy by Inducing Paraptosis and Apoptosis,” Journal of Controlled Release 336 (2021): 159–168.

[36] L. P. Zhao, X. N. Rao, R. R. Zheng, et al., “Carrier-Free Nano-Protacs to Amplify Photodynamic Therapy Induced DNA Damage Through BRD4 Degradation,” Nano Letters 23 (2023): 6193–6201.

[37] F. Fang, S. Wang, Y. Song, et al., “Continuous Spatiotemporal Therapy of a Full-API Nanodrug via Multi-Step Tandem Endogenous Biosynthesis,” Nature Communications 14 (2023): 1660.

[38] L. P. Zhao, J. Q. Li, G. M. Chen, et al, “Cuproptosis Amplifier of Copper-Telaglenastat Coordinate to Trigger Cell Ferroptosis for Synergistic Breast Cancer Suppression,” Chinese Chemical Letters (2025): 110959.

[39] L. H. Liu and X. Z. Zhang, “Carrier-Free Nanomedicines for Cancer Treatment,” Progress in Materials Science 125 (2022): 100919.

[40] W. Wu, L. Yu, Q. Jiang, et al., “Enhanced Tumor-Specific Disulfiram Chemotherapy by In Situ Cu2+ Chelation-Initiated Nontoxicity-to-Toxicity Transition,” Journal of the American Chemical Society 141 (2019): 11531–11539.

[41] X. Wang, W. Su, Y. Jiang, et al., “Regulation of Nucleotide Metabolism With Nutrient-Sensing Nanodrugs for Cancer Therapy,” Advanced Science 9 (2022): 2200482.

[42] A. Guan, Y. Fan, S. Xi, et al., “Nitrogen-Adsorbed Hydrogen Species Promote CO2 Methanation on Cu Single-Atom Electrocatalyst,” ACS Materials Letters 5 (2023): 19–26.

[43] D. Chen, L. H. Zhang, J. Du, et al., “A Tandem Strategy for Enhancing Electrochemical CO2 Reduction Activity of Single-Atom Cu-S1 N3 Catalysts via Integration With Cu Nanoclusters,” Angewandte Chemie International Edition 60 (2021): 24022–24027.

[44] C. Jiang, N. P. Ward, N. Prieto-Farigua, et al., “A Crispr Screen Identifies Redox Vulnerabilities for KEAP1/NRF2 Mutant Non-Small Cell Lung Cancer,” Redox Biology 54 (2022): 102358.

[45] L. Dai, X. Li, X. Duan, et al, “A pH/ROS Cascade-Responsive Charge-Reversal Nanosystem With Self-Amplified Drug Release for Synergistic Oxidation-Chemotherapy,” Advancement of Science 6 (2018): 1801807.

[46] E. A. Motea, X. Huang, N. Singh, et al., “NQO1-Dependent, Tumor-Selective Radiosensitization of Non-Small Cell Lung Cancers,” Clinical Cancer Research 25 (2019): 2601–2609.

[47] M. T. Manzari, Y. Shamay, H. Kiguchi, N. Rosen, M. Scaltriti, and D. A. Heller, “Targeted Drug Delivery Strategies for Precision Medicines,” Nature Reviews Materials 6 (2021): 351–370.

[48] Y. Lu, T. Zeng, H. Zhang, et al., “Nano-Immunotherapy for Lung Cancer,” Nano TransMed 2 (2023): e9130018.

[49] X. Wang, M. Wu, H. Li, et al., “Enhancing Penetration Ability of Semiconducting Polymer Nanoparticles for Sonodynamic Therapy of Large Solid Tumor,” Advanced Science 9 (2022): 2104125.

[50] V. Kumar, V. Mundra, Y. Peng, Y. Wang, C. Tan, and R. I. Mahato, “Pharmacokinetics and Biodistribution of Polymeric Micelles Containing miRNA and Small-Molecule Drug in Orthotopic Pancreatic Tumor-Bearing Mice,” Theranostics 8 (2018): 4033–4049.

[51] A. S. Dejean, D. R. Beisner, I. L. Ch'en, et al., “Transcription Factor Foxo3 Controls the Magnitude of T Cell Immune Responses by Modulating the Function of Dendritic Cells,” Nature Immunology 10 (2009): 504–513.

[52] A. M. Monjazeb, M. S. Kent, S. K. Grossenbacher, et al., “Blocking indolamine-2,3-dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies,” Clinical Cancer Research 22 (2016): 4328–4340.

[53] A. Amobi, F. Qian, A. A. Lugade, et al., “Tryptophan Catabolism and Cancer Immunotherapy Targeting IDO Mediated Immune Suppression,” Advances in Experimental Medicine and Biology 1036 (2017): 129–144.

[54] Y. Zhang, C. Li, C. Xia, et al., “Adagrasib, a KRAS G12C Inhibitor, Reverses the Multidrug Resistance Mediated by ABCB1 In Vitro and In Vivo,” Cell Communication and Signaling 20 (2022): 142.

[55] Y. Hou, H. L. Liang, X. Yu, et al., “Radiotherapy and Immunotherapy Converge on Elimination of Tumor-Promoting Erythroid Progenitor Cells Through Adaptive Immunity,” Science Translational Medicine 13 (2021): eabb0130.

[56] K. A. Sullivan, S. R. Bever, D. B. McKim, et al., “Mammary Tumors Compromise Time-of-Day Differences in Hypothalamic Gene Expression and Circadian Behavior and Physiology in Mice,” Brain, Behavior, and Immunity 80 (2019): 805–817.

[57] F. Fang and X. Chen, “Carrier-Free Nanodrugs: From Bench to Bedside,” ACS Nano 18 (2024): 23827–23841.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm – Biomaterials and Applications published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).